A Novel Correlation between LINE-1 Hypomethylation and the Malignancy of Gastrointestinal Stromal Tumors

Shinichi Igarashi1, Hiromu Suzuki1,2, Takeshi Niinuma1, Haruo Shimizu1,8, Masanori Nojima1,3, Hiroyuki Iwaki9, Takayuki Nobuoka4, Toshirou Nishida10,11, Yasuaki Miyazaki13, Hiroyuki Takamaru1, Eiichiro Yamamoto1,2, Hiroyuki Yamamoto1, Takashi Tokino5, Tadashi Hasegawa6, Koichi Hirata6, Kohzoh Imaizumi7, Minoru Toyoda7, and Yasuhiro Shinomura1

Abstract

Purpose: Gastrointestinal stromal tumors (GIST) are the most important mesenchymal tumors of the gastrointestinal tract. The vast majority of GISTs exhibit activating mutations of KIT or PDGFRα, but epigenetic alteration of GISTs is largely unknown. In this study, we aimed to clarify the involvement of DNA methylation in GIST malignancy.

Experimental Design: A total of 106 GIST specimens were studied. Levels of LINE-1 methylation were analyzed using bisulfite pyrosequencing. In addition, methylation of three other repetitive sequences (Alu Yb8, Satellite-α, and NBL2) was similarly analyzed, and CpG island hypermethylation was analyzed using MethyLight. Array-based comparative genomic hybridization (array CGH) was carried out in 25 GIST specimens.

Results: LINE-1 hypomethylation was significantly correlated with risk, and high-risk GISTs exhibited significantly lower levels of LINE-1 methylation than low-risk (61.3% versus 53.2%; P = 0.001) or intermediate-risk GISTs (60.8% versus 53.2%; P = 0.002). Hypomethylation of Satellite-α and NBL2 was also observed in high-risk GISTs. By contrast, promoter hypermethylation was relatively infrequent (CDH1, 11.2%; MLH1, 9.8%; SFRP1, 1.2%; SFRP2, 11.0%; CHFR, 9.8%; APC, 6.1%; CDKN2A, 0%; RASSF1A, 0%; RASSF2, 0%) and did not correlate with LINE-1 methylation or risk. Array CGH analysis revealed a significant correlation between LINE-1 hypomethylation and chromosomal aberrations.

Conclusions: Our data suggest that LINE-1 hypomethylation correlates significantly with the aggressiveness of GISTs and that LINE-1 methylation could be a useful marker for risk assessment. Hypomethylation may increase the malignant potential of GISTs by inducing accumulation of chromosomal aberrations. Clin Cancer Res; 16(21); 5114–23. ©2010 AACR.

Gastrointestinal stromal tumors (GIST), which consist of a spectrum of both benign and malignant tumors, constitute the most important group of primary mesenchymal tumors of the gastrointestinal tract (1, 2). Immunohistochemically, GISTs are positive for KIT and CD34 and are negative or variably positive for other neural and smooth muscle cell markers. The expression of KIT and CD34 is a characteristic feature of the intestinal cells of Cajal (ICC), which are located in the intestinal wall and regulate gastrointestinal motility. GISTs are thus thought to originate from ICCs or ICC precursors. Activating KIT mutations have been identified in 80% to 90% of GISTs, and mutation of the platelet-derived growth factor receptor α gene (PDGFRα) is observed in ~5% of GISTs (1–3). In that context, imatinib (formerly STI571) was developed as a tyrosine kinase inhibitor and has been shown to inhibit BCR-ABL, KIT, and PDGFR activities (1–3). Imatinib is currently being used for the treatment of both chronic myeloid leukemia and metastatic GISTs.

Authors’ Affiliations: †First Department of Internal Medicine, Sapporo Medical University; ‡Department of Biochemistry, Sapporo Medical University; §Department of Public Health, Sapporo Medical University; †First Department of Surgery, Sapporo Medical University; ‡Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University; §Department of Surgical Pathology, Sapporo Medical University; †The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; ‡Department of Gastroenterology, Muroran General Hospital, Muroran, Japan; §Department of Pathology, Sunagawa City Medical Center, Sunagawa Japan; and †Department of Surgery, Osaka Police Hospital; ‡Department of Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

S. Igarashi and H. Suzuki contributed equally to this work.

Corresponding Authors: Shinomura Yasuhiro, First Department of Internal Medicine, Sapporo Medical University, S1, W16, Chuo-ku, Sapporo 060-8543, Japan. Phone: 81-11-611-2111; Fax: 81-11-611-2282; E-mail: shinomura@sapmed.ac.jp. or Minoru Toyota, Department of Biochemistry, Sapporo Medical University, S1, W17, Chuo-ku, Sapporo 060-8558, Japan. Phone: 81-11-611-2111; Fax: 81-11-622-1918; E-mail: mtoyoda@sapmed.ac.jp.

doi: 10.1158/1078-0432.CCR-10-0581

©2010 American Association for Cancer Research.
Recently reported that hypomethylation is known to occur during the development of various human malignancies (9). Moreover, hypomethylation of such repetitive elements can serve as a surrogate (SINE; ref. 7), and an earlier study has shown that methylation of long interspersed nuclear element (LINE) and short interspersed nuclear element repetitive sequences also has been observed in tumors of various origin (15–20). To date, however, only a few groups have reported epigenetic abnormalities in GISTs (21–24), and there are no published studies of LINE-1 methylation in GISTs.

Our aim in the present study was to assess the contribution made by epigenetic alterations to the malignant potential of GISTs. We quantitatively analyzed levels of LINE-1 methylation, and also assessed CpG island hypermethylation in a panel of tumor-associated genes in primary GIST specimens. In addition, we carried out an array-based comparative genomic hybridization (array CGH) analysis to examine the relation between chromosomal aberrations and LINE-1 hypomethylation in GISTs.

Materials and Methods

Patients and tumor tissues

A total of 106 GIST specimens were obtained from Sapporo Medical University Hospital, Sunagawa City Medical Center, Muroran General Hospital, and Osaka University Hospital. Informed consent was obtained from all patients before collection of the specimens, and this study was approved by the respective institutional review boards. Risk grade was assessed according to the risk definition system proposed by Fletcher et al. (4). Tumors that were <2 cm in diameter with a mitotic count of <5/50 high-power fields (HPF) were categorized as very low risk. Tumors that were 2 to 5 cm in diameter with a mitotic count of 5 to 10 HPF, or were 5 to 10 cm with a mitotic count <5/50 HPF, were considered intermediate risk. Tumors that were >5 cm in diameter with a mitotic count of >5/50 HPF, >10 cm in diameter with any mitotic count, or any size with a mitotic count of >10/50 HPF were considered to be high risk. Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue specimens using a QIAamp DNA FFPE Tissue kit (Qiagen). Genomic DNA was extracted from fresh-frozen tissue specimens using the standard phenol-chloroform procedure.

Bisulfite pyrosequencing

Genomic DNA (1 μg) was modified with sodium bisulfite using an Epitexit Bisulfite kit (Qiagen), and bisulfite pyrosequencing analysis was done as described previously (14). Briefly, PCR was run in a 25-μL volume containing 50 ng of bisulfite-treated DNA, 1× MSP buffer [67 mmol/L Tris-HCl (pH 8.8), 16.6 mmol/L (NH₄)₂SO₄, 6.7 mmol/L MgCl₂, and 10 mmol/L 2-mercaptoethanol], 1.25 mmol/L dideoxynucleotide triphosphate, 0.4 μmol/L each primer, and 0.5 unit of JumpStart RED Taq DNA Polymerase (Sigma-Aldrich). The PCR protocol for bisulfite sequencing entailed 5 minutes at 95°C; 40 cycles of 1 minute at 95°C, 1 minute at 60°C, and 1 minute at 72°C; and a 7-minute final extension at 72°C. The biotinylated PCR product was purified, made single stranded, and used as a template in a pyrosequencing reaction run according to the manufacturer's protocol.
instructions. The PCR products were bound to Streptavidin Sepharose HP beads (Amersham Biosciences), after which beads containing the immobilized PCR product were purified, washed, and denatured using a 0.2 mol/L NaOH solution. After addition of 0.3 μmol/L sequencing primer to the purified PCR product, pyrosequencing was carried out using a PSQ96MA system (Biotage) and Pyro Q-CpG software (Biotage). Primer sequences for LINE-1 methylation were as described (14). Primer sequences for Alu Yb8, centromeric satellite-α of chromosome 1 (Sat-α), and NBL2 were as described (20).

**MethyLight assay**

Genomic DNA (1 μg) was modified with sodium bisulfite as described above. PCR was run in a 20-μL volume containing 50 ng of bisulfite-treated DNA, 625 nmol/L each primer, 250 nmol/L Taqman-MGB probe, and 1× Taqman Fast Universal PCR Master Mix (Applied Biosystems). Fast real-time PCR was done using a 7500 Fast Real-Time PCR System according to the manufacturer’s instructions (Applied Biosystems). The PCR protocol entailed 20 seconds at 95°C followed by 40 cycles of 3 seconds at 95°C and 30 seconds at 60°C. We used Alu as a normalization control reaction (25). Primers, probes, and the percentage of methylated reference (PMR) were as described previously (26, 27). We used a PMR cutoff of 4 to distinguish methylation-positive (PMR > 4) from methylation-negative (PMR ≤ 4) samples (27).

**Array-based comparative genomic hybridization**

Microarray-based CGH analysis was done according to the manufacturer's instructions (Agilent Technologies). Briefly, 500 ng of genomic DNA from fresh-frozen GIST specimens and gender-matched reference DNA (Promega) were digested with Alul and RsaI before labeling and hybridization. Using a Genomic DNA Enzymatic Labeling kit (Agilent Technologies), tumor DNA and reference DNA were labeled with Cy5 and Cy3, respectively. Before hybridization, labeled DNA was mixed with 25 μg of Cot-1 DNA (Invitrogen), denatured at 95°C for 3 minutes, and incubated at 37°C for 30 minutes to block repetitive sequences. The probe mixture was then hybridized for 40 hours at 65°C to a Human Genome CGH Microarray Kit 105A (G4412A; Agilent Technologies), which contains ~99,000 probes annotated against National Center for Biotechnology Information Build 36. After washing, the array was scanned with an Agilent G2565BA Microarray Scanner, and the fluorescent signals were acquired using Feature Extraction software (Agilent Technologies). The ADM-2 algorithm included in the DNA Analytics 4.0 software (Agilent Technologies) was used to identify DNA copy number aberrations. A copy number loss was defined as a log2 ratio <−0.5, and a copy number gain was defined as a log2 ratio >0.5. All genomic positions were defined according to the University of California Santa Cruz Human version hg18. The Gene Expression Omnibus accession numbers of the microarray data are GSM552407, GSM552408, GSM552409, GSM552410, GSM552411, GSM552412, GSM552413, GSM552414, GSM552415, GSM552416, GSM552417, GSM552418, GSM552419, GSM552420, GSM552421, GSM552422, GSM552423, GSM552424, GSM552425, and GSM552426, and the accession number of the Series entry is GSE22185.

**Statistical analysis**

Mean methylation levels were compared using t tests or one-way ANOVA with a post hoc Games-Howell test. Methylation levels were correlated with other biological features by calculating the Pearson's and Spearman's correlation coefficients. LINE-1 methylation levels were categorized into four groups: greater than 1 SD (1 – SD) above the mean, plus/minus 1 – SD from the mean, and less than 1 – SD below the mean. Sex- and age-adjusted odds ratios (OR) for high-risk category were then calculated using logistic regression models. P values of <0.05 (two-sided) were considered significant. Statistical analyses were carried out using Statistical Package for the Social Sciences software 15.01 (SPSS, Inc.) and StatView (SAS Institute, Inc.).

**Results**

**Clinicopathologic characteristics**

The clinicopathologic features of the 106 patients with primary GISTs are summarized in Table 1. The majority of the GISTs were located in the stomach (65%) and small intestine (27%), and the mean tumor size was 6.9 cm (range, 0.5–22 cm). The risk classification proposed by Fletcher et al. (4) was available for 85 patients. Of those,
1 (1.2%) was classified as very low risk, 23 (27.1%) were low risk, 19 (22.3%) were intermediate risk, and 42 (49.4%) were high risk. Among the 42 patients in the high-risk group, metastasis was found in 14 (33.3%).

**Hypomethylation of LINE-1 in GISTs**

We next asked whether global DNA hypomethylation is involved in the development of GISTs. To address this question, we carried out bisulfite pyrosequencing to quantitatively analyze LINE-1 promoter methylation as a surrogate for global methylcytosine content. All of the samples were analyzed at least twice, and the results of independent analyses were highly reproducible (Supplementary Fig. S1). We found that the mean level of LINE-1 methylation in the 106 GIST specimens was 57.3 ± 9.3% (mean ± SD; range, 27.9-74.1%), and that the level was slightly lower in female patients than male patients, although the difference was not statistically significant (male, 58.8%; female, 55.9%; \( P = 0.055 \)). We found no correlation between tumor location and LINE-1 methylation (stomach, 58.6%; small intestine, 54.4%; esophagus, 51.9%; omentum, 57.7%; colon, 56.2%; \( P = 0.4136 \)), and there was no correlation between age and LINE-1 methylation (<60 years, 56.5%; 61-70 years, 58.8%; >71 years, 57.9%; \( P = 0.687 \)).

We then compared LINE-1 methylation with risk classification. The single very low-risk GIST specimen showed a high level of LINE-1 methylation (74.1%). Low-risk (\( n = 23 \)) and intermediate-risk (\( n = 19 \)) GISTs showed similar levels of LINE-1 methylation (61.3% versus 60.8%). By contrast, high-risk GISTs (\( n = 42 \)) exhibited a significantly lower level of LINE-1 methylation (53.2%) than GISTs in the other risk groups (Fig. 1A). Using that information, we stratified the tumors according to their level of LINE-1 methylation, which was then correlated with the risk categories. After adjusting for age and gender, the lowest level of LINE-1 methylation (<54.9%) was significantly associated with the high-risk category [OR, 7.5; 95%

**Table 2. Correlation between LINE-1 methylation and the GIST risk category**

<table>
<thead>
<tr>
<th>LINE-1 methylation (%)</th>
<th>All samples (( N = 76 ))</th>
<th>High-risk (( n = 36 ))</th>
<th>Very low-, low-, or intermediate-risk (( n = 40 ))</th>
<th>( P )</th>
<th>OR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;68.0</td>
<td>13</td>
<td>4</td>
<td>9</td>
<td></td>
<td>1.0</td>
</tr>
<tr>
<td>61.4-67.9</td>
<td>14</td>
<td>4</td>
<td>10</td>
<td>0.976</td>
<td>1.0 (0.2-5.5)</td>
</tr>
<tr>
<td>54.9-61.3</td>
<td>22</td>
<td>8</td>
<td>14</td>
<td>0.638</td>
<td>1.4 (0.3-6.5)</td>
</tr>
<tr>
<td>&lt;54.9</td>
<td>27</td>
<td>20</td>
<td>7</td>
<td>0.009</td>
<td>7.5 (1.6-34.0)</td>
</tr>
</tbody>
</table>

\( P \) trend < 0.001

*Age- and gender-adjusted OR.
Moreover, bivariate correlation analysis revealed an inverse correlation between LINE-1 methylation levels and tumor size (Fig. 1B). Among the high-risk GIST patients, LINE-1 methylation was slightly lower in individuals with incidences of metastasis than in those without metastasis (50.0% versus 54.8%), although the difference was not statistically significant (Fig. 1C). However, when we divided high-risk GIST patients into two groups according to LINE-1 methylation and did logistic regression analysis, we found that GISTs with lower LINE-1 methylation (<55%) were significantly associated with incidences of metastasis (OR, 9.5; 95% CI, 1.5-61.2; Supplementary Table S1). These results suggest that LINE-1 hypomethylation is strongly associated with greater risk and aggressiveness of GISTs.

### Hypomethylation of other repetitive DNA elements in GIST

Previous studies showed that Alu elements and other repetitive sequences are also hypomethylated in human malignancies (15–20). We therefore carried out bisulfite pyrosequencing of Alu Yb8 and two other tandem repeats, Sat-α and NBL2, which are reportedly hypomethylated in cancer (15, 20). We found a moderate correlation between LINE-1 methylation and Alu Yb8 methylation (Fig. 2A); however, levels of Alu Yb8 methylation did not significantly correlate with risk grade (Fig. 2B). By contrast, LINE-1 methylation strongly correlated with Sat-α and NBL2 methylation (Fig. 2A). High-risk GISTs showed significantly lower levels of Sat-α methylation than low-risk (57.9% versus 73.9%) or intermediate-risk GISTs (57.9% versus 76.3%; Fig. 2B), and significantly lower levels of NBL2 methylation than low-risk GISTs (65.1% versus 75.5%; Fig. 2B).

### Analysis of CpG island hypermethylation of tumor-related genes

Because it was previously reported that CpG island methylation correlates with GIST malignancy (21), we next assessed the methylation levels of the CpG islands of several well-characterized tumor suppressor and tumor-related genes in the GIST specimens. Using MethyLight...
assays, we analyzed nine genes frequently methylated in gastrointestinal cancers. Unexpectedly, methylation of these genes was relatively infrequent in GISTs (CDH1, 12.2%; MLH1, 9.8%; SFRP1, 1.2%; SFRP2, 11.0%; CHFR, 9.8%; APC, 6.1%; CDKN2A, 0%; RASSF1A, 0%; RASSF2, 0%; Supplementary Table S2). Interestingly, however, CDH1 tended to be methylated more frequently in higher-risk GISTs, whereas MLH1 tended to be methylated less frequently, although these correlations were not statistically significant (Supplementary Table S2). We failed to find any significant correlation between methylation of other genes and clinicopathologic features. There was also no significant correlation between CpG island methylation and LINE-1 hypomethylation.

Association of LINE-1 methylation with chromosomal aberrations

The biological meaning of global hypomethylation in tumors is not yet fully understood, but it is thought to be associated with chromosomal instability (5). Consistent with that idea, earlier cytogenetic, fluorescence in situ hybridization, and CGH studies revealed frequent chromosomal imbalances in GISTs (28–32). This prompted us to ask whether LINE-1 hypomethylation in GISTs is associated with chromosomal gain or loss. We addressed that question by carrying out an array CGH analysis using 25 freshly frozen GIST specimens using an Agilent 105K oligonucleotide microarray.

We found that the average number of chromosomal aberrations for a given tumor was 28.5 (range, 5–62), and genomic losses were much more common than gains. Consistent with previous CGH and array CGH studies of GIST (28–32), we observed frequent genomic losses at 14q (92%), 22q (68%), 15q (64%), and 1p (60%; Table 3; Supplementary Fig. S2; Supplementary Table S3). Total or partial losses at 14q were the most frequent chromosomal aberration (23 of 25; 92%), and 17 GISTs showed a total loss of chromosome 14. Total or partial losses of 22q were also frequently detected (17 of 25; 68%), and 11 tumors showed a loss of the whole chromosome. Losses at 1p were detected in 15 of 25 tumors (60%), and losses were generally more frequent in intestinal GISTs than in gastric ones (Table 3). Losses at 15q were often associated with 1p loss, which is consistent with an earlier observation.

<table>
<thead>
<tr>
<th>No.</th>
<th>Age/gender</th>
<th>Location</th>
<th>Risk</th>
<th>L-1 (%)</th>
<th>1p</th>
<th>3q</th>
<th>4q</th>
<th>9p</th>
<th>13q</th>
<th>14q</th>
<th>15q</th>
<th>22q</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67/M</td>
<td>Stomach</td>
<td>Low</td>
<td>71.2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>65/M</td>
<td>Stomach</td>
<td>Inter.</td>
<td>71.1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>64/F</td>
<td>Stomach</td>
<td>Low</td>
<td>70.1</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>50/M</td>
<td>Stomach</td>
<td>Low</td>
<td>69.5</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>27/F</td>
<td>Stomach</td>
<td>Inter.</td>
<td>68.8</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>68/F</td>
<td>Stomach</td>
<td>Low</td>
<td>68.6</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>61/M</td>
<td>Small intestine</td>
<td>Low</td>
<td>67.6</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
</tr>
<tr>
<td>8</td>
<td>62/F</td>
<td>Stomach</td>
<td>Low</td>
<td>64.7</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>65/F</td>
<td>Stomach</td>
<td>Low</td>
<td>64.0</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>25/F</td>
<td>Small intestine</td>
<td>Low</td>
<td>60.5</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
</tr>
<tr>
<td>11</td>
<td>70/M</td>
<td>Stomach</td>
<td>Low</td>
<td>60.3</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
</tr>
<tr>
<td>12</td>
<td>53/F</td>
<td>Stomach</td>
<td>High</td>
<td>58.3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
</tr>
<tr>
<td>13</td>
<td>56/M</td>
<td>Small intestine</td>
<td>Low</td>
<td>56.6</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>14</td>
<td>65/M</td>
<td>Stomach</td>
<td>High</td>
<td>56.0</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>15</td>
<td>37/M</td>
<td>Small intestine</td>
<td>High</td>
<td>55.2</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>16</td>
<td>63/M</td>
<td>Stomach</td>
<td>Inter.</td>
<td>55.0</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>17</td>
<td>73/F</td>
<td>Stomach</td>
<td>High</td>
<td>52.7</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>18</td>
<td>68/F</td>
<td>Small intestine</td>
<td>High</td>
<td>52.5</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>19</td>
<td>62/M</td>
<td>Small intestine</td>
<td>High</td>
<td>51.5</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>20</td>
<td>57/M</td>
<td>Small intestine</td>
<td>High</td>
<td>50.3</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>21</td>
<td>49/M</td>
<td>Stomach</td>
<td>NA</td>
<td>49.7</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>22</td>
<td>68/M</td>
<td>Small intestine</td>
<td>NA</td>
<td>49.5</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>23</td>
<td>73/F</td>
<td>Stomach</td>
<td>High</td>
<td>47.0</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>24</td>
<td>87/M</td>
<td>Small intestine</td>
<td>High</td>
<td>44.0</td>
<td>Yes*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
<tr>
<td>25</td>
<td>68/F</td>
<td>Stomach</td>
<td>High</td>
<td>33.4</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes*</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: L-1, LINE-1 methylation; Inter., intermediate; NA, not available.

*Loss of the entire p- or q-arm of the chromosome.
Partial losses at 3q were also frequently detected (19 of 25; 76%), and a minimal common overlapping region was identified at 3q26.1, although this region contains no annotated genes (Supplementary Table S3). In addition, losses at 4q13.2, the locus of UGT2B17/UGT2B28, were detected in 20 of 25 tumors (80%). Losses at 9p were found in 11 of 25 (44%) GISTs, and 4 tumors showed a loss of the whole p-arm. Among seven tumors with partial 9p losses, four showed a loss at 9p21, the locus of CDKN2A/CDKN2B.

Losses at 3q, 4q, 14q, and 22q were found to be equally distributed in tumors with all levels of LINE-1 methylation (Table 3). By contrast, many other chromosomal aberrations correlated with LINE-1 hypomethylation (Table 3; Fig. 3A). For example, GISTs with losses at 1p showed significantly lower LINE-1 methylation than those without 1p loss (53.8% versus 64.1%; \( P = 0.007 \)). LINE-1 methylation was also much lower in tumors with loss at 9p than in those without that loss (52.1% versus 62.5%; \( P = 0.005 \)). Bivariate correlation analysis revealed a significant inverse correlation between levels of LINE-1 methylation and the total number of chromosomal aberrations, including both losses and gains (Fig. 3B). These results suggest a significant relationship between LINE-1 hypomethylation and DNA copy number abnormalities in GIST.

**Discussion**

Although several studies have shown that genetic abnormalities, including various mutations and chromosomal imbalances, are significantly involved in the development of GISTs, little is known about the role played by epigenetic alterations in these tumors. To date, there had been only a few reports of Cpg island methylation in GISTs (21–24), and levels of global DNA methylation had not yet been analyzed. In the present study, however, we found that levels of methylation of LINE-1 and other repetitive elements are reduced in GISTs. It has been known for decades that global hypomethylation is a common feature of human cancer (33, 34), and in recent years, hypomethylation has been studied in various human malignancies using LINE-1 and other repetitive sequences as surrogates.
(9–20). Our results confirm that GISTs exhibit a pattern of hypomethylation that is similar to those exhibited by many other human tumors.

We found that LINE-1 hypomethylation is strongly associated with the aggressiveness of GISTs. Levels of LINE-1 methylation were significantly lower in high-risk GISTs than in low- or intermediate-risk tumors. In addition, levels of LINE-1 methylation inversely correlated with tumor size and mitotic counts. These results are consistent with earlier observations that a reduction in global methyllysine content is associated with malignant potential in cancer, and that it is especially prevalent in metastatic tumors (34). LINE-1 hypomethylation is also reportedly associated with poor prognosis in prostate (17), colon (35), and ovarian (36) cancers and in chronic myeloid leukemia (11). In normal cells, DNA methylation plays important roles in X-chromosome inactivation, genomic imprinting, and repression of repetitive elements, such as retrotransposons and endogenous retroviruses. Thus, hypomethylation may also be associated with tumor malignancy through a variety of mechanisms. For example, global hypomethylation is associated with genomic instability (37–40), which may confer a poor prognosis. Hypomethylation can also lead to activation of proto-oncogenes, endogenous retroviruses, or transposable elements, and such transcriptional dysregulation could affect tumor aggressiveness.

We found strong correlations between the level of LINE-1 methylation and methylation of other repetitive elements. Sat-α and NBL2, which are tandem DNA repeats, are reportedly hypomethylated in various human cancers (15, 16, 20, 41). We observed that methylation of these elements is also reduced in high-risk GISTs, which suggests that a common mechanism may induce and maintain DNA hypomethylation in tumors. On the other hand, LINE-1 methylation correlated only moderately with Alu Yb8 methylation, and hypomethylation of Alu Yb8 was limited, even in high-risk GISTs. Similar modest correlation between LINE-1 and Alu methylation was also observed in head and neck squamous cell carcinomas and neuroendocrine tumors (18, 42). This lower correlation may simply reflect a difference in assay sensitivity, although it is possible that there are functional and/or biological differences in the regulation of these two types of repetitive DNA elements.

Although global hypomethylation and regional hypermethylation of 5′ CpG islands are common features of neoplasias, the link between the two remains controversial. Recent studies using methylation of LINE-1 and/or Alu as a marker revealed that global hypomethylation is correlated with CpG island hypermethylation in prostate cancers (17) and neuroendocrine tumors (42). In addition, we recently showed that LINE-1 hypomethylation and CpG island hypermethylation are tightly linked in enlarged fold gastritis (14). By contrast, others did not find a similar relationship in Wilm's tumor (41), colon cancer (43), or ovarian cancer (16). Recent studies also revealed that LINE-1 hypomethylation is inversely correlated with microsomal instability and/or the CpG island methylator phenotype in colon cancer, suggesting that CpG island hypermethylation and global hypomethylation may reflect different tumor progression pathways (12, 13). In the present study, we failed to find a significant correlation between 5′ CpG island hypermethylation of tumor-related genes and global hypomethylation. However, this may reflect a bias toward selection of genes frequently methylated in tumors of epithelial origin, as GISTs may exhibit methylation of a different spectrum of genes.

House et al. (21) reported that hypermethylation of CDH1 (E-cadherin) is positively correlated with GISTs having malignant histologic features (mitotic rate, tumor size, and necrosis) and a poor prognosis. In addition, the presence of CDH1 methylation and the absence of MLH1 methylation correlated with early tumor recurrence. By contrast, Saito et al. (24) reported that CpG island hypermethylation, including that of MLH1 and CDH1, was frequently detected in GISTs, irrespective of their malignancy. In the present study, we found tendencies for CDH1 methylation to occur more frequently and MLH1 methylation to occur less frequently in higher-risk GISTs, although these correlations were not statistically significant. We also noticed that the frequencies of CpG island methylation were lower than those reported previously (21, 24). This could reflect differences in the primer sequences used in our study, but the actual reason for the discrepancy is not clear. As mentioned above, GISTs may exhibit hypermethylation of a different spectrum of genes, and further study will be needed to clarify the role of CpG island methylation in GISTs.

Global hypomethylation is strongly implicated in chromosomal instability. A study using Nf1<sup>+/−</sup> P53<sup>−/−</sup> mice has shown that introduction of a hypomorphic Dnmt1 allele causes DNA hypomethylation that leads to significant increases in the loss of heterozygosity rate and tumor development (37). Another study has shown that hypomethylation in Apc<sup>Min+/−</sup> mice leads to increases in microadenoma formation through loss of heterozygosity at the Apc locus (38). Global hypomethylation also correlates with chromosomal instability and copy number changes in human cancers (18, 19, 39, 40). Thus, to assess the potential implication of LINE-1 hypomethylation in genomic instability in GISTs, we carried out an array CGH analysis and correlated hypomethylation with chromosomal imbalances. The results of this analysis are largely consistent with previously reported cytogenetic, CGH, and array CGH analyses of GISTs (28–32). In general, losses were more common than gains, and genomic losses frequently affected 1p, 14q, 15q, and 22q. In addition, we found losses at 3q26.1 and 4q13.2, the locus of UGT2B17/UGT2B28, in the majority of tumors tested. UGT2B17, which is a member of the UDP-glucuronosyltransferases (UGT) family, has been implicated in the metabolism of androgens, and a deletion polymorphism in UGT2B17 is reportedly associated with the risk of prostate cancer (44), although its functional role in GISTs remains to be clarified.
Although the most frequent aberrations (e.g., losses of 14q and 22q) were equally distributed among GISTs with all levels of LINE-1 methylation, we found a significant correlation between many other chromosomal aberrations and DNA hypomethylation. For instance, tumors with losses at 1p or 9p showed significantly lower LINE-1 methylation. Notably, these results are consistent with previous findings that losses at 14q and 22q are early changes in GIST development, whereas losses at 1p and 9p are associated with malignancy and poor prognosis (28–31). Moreover, total numbers of chromosomal aberrations are highly correlated with LINE-1 hypomethylation. It thus seems that LINE-1 hypomethylation may play an important role in inducing chromosomal aberrations and increasing the aggressiveness of GISTs. Currently, however, we have no functional evidence of a causal relationship between hypomethylation and the genomic instability of GISTs, and further studies will be required to clarify the underlying molecular mechanism.

In summary, we found that hypomethylation of repetitive elements is associated with high-risk GISTs. We also provide further evidence that LINE-1 hypomethylation is strongly associated with chromosomal aberrations. Although the cause of DNA hypomethylation in GISTs remains unclear, LINE-1 methylation could be a useful marker for predicting the risk and prognosis of the disease.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. William F. Goldman for editing the manuscript and M. Ashida for technical assistance.

Grant Support

Grants-in-Aid for Scientific Research on Priority Areas (M. Toyota and K. Imai), Program for developing the supporting system for upgrading the education and research from the Ministry of Education, Culture, Sports, Science, and Technology (Y. Shinomura and M. Toyota), A3 foresight program from the Japan Society for Promotion of Science (H. Suzuki), Grants-in-Aid for Scientific Research (B) from the Japan Society for Promotion of Science (Y. Shinomura), Grants-in-Aid for Scientific Research (S) from the Japan Society for Promotion of Science (K. Imai), a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy for Cancer Control (M. Toyota), and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan (M. Toyota).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 03/06/2010; revised 06/08/2010; accepted 06/20/2010; published OnlineFirst 10/26/2010.

References


A Novel Correlation between LINE-1 Hypomethylation and the Malignancy of Gastrointestinal Stromal Tumors

Shinichi Igarashi, Hiromu Suzuki, Takeshi Niinuma, et al.